Physician profile
Todd Heller
NPI 1053305763
$21,667.30
in general payments reported to CMS, 2019-2025
44 companies · $1,323 in 2025
The $1,323 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,338 · 2020: $1,403 · 2021: $1,671 · 2022: $13K · 2023: $1,408 · 2024: $1,265 · 2025: $1,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,967 · Education: $30.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,966.66 |
| Education | $30.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $11,297.71 | 2021-2022 | |
| Abbvie INC. | $3,817.54 | 2019-2025 | |
| Janssen Biotech, INC. | $1,081.13 | 2019-2025 | Tremfya, Stelara, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $822.48 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $635.70 | 2019-2024 | Xifaxan |
| Amgen INC. | $410.07 | 2020-2023 | Avsola, Amjevita |
| Pfizer INC. | $347.20 | 2019-2025 | |
| Celgene Corporation | $309.53 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $248.71 | 2019-2025 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $235.74 | 2019-2022 | |
| Ardelyx, INC. | $204.72 | 2022-2024 | Ibsrela |
| Qol Medical, LLC | $168.06 | 2019-2025 | Sucraid |
| Gilead Sciences, INC. | $157.77 | 2019-2022 | |
| Genzyme Corporation | $153.38 | 2024-2025 | |
| Redhill Biopharma INC. | $150.08 | 2020-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Heller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.